PDCD1 and non-small cell lung carcinoma: For this, we combined the anti-DBI/ACBP mAb with chemoimmunotherapy (which is the current standard of care for many cancers, i.e., chemotherapy together with immunotherapy targeting PDCD1) against two types of cancers, namely NSCLC and cutaneous sarcoma.